Oncimmune Holdings plc (LON:ONC – Get Free Report) was down 2.5% on Thursday . The company traded as low as GBX 8 ($0.10) and last traded at GBX 9.95 ($0.12). Approximately 378,794 shares changed hands during trading, an increase of 34% from the average daily volume of 281,822 shares. The stock had previously closed at GBX 10.20 ($0.13).
Oncimmune Stock Performance
The company has a 50 day simple moving average of GBX 13.59 and a 200-day simple moving average of GBX 14.82. The company has a debt-to-equity ratio of 806.85, a current ratio of 1.13 and a quick ratio of 0.63. The stock has a market cap of £7.19 million, a P/E ratio of -323.40 and a beta of 1.19.
About Oncimmune
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.
Recommended Stories
- Five stocks we like better than Oncimmune
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Most active stocks: Dollar volume vs share volume
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.
